Research projects in Immuno-Inflammation

Our projects aim to understand the regulatory mechanisms of inflammation and to develop immunotherapeutic strategies (new molecules or cell subpopulations) to control inflammatory responses in different pathological contexts.

Research projects in Immuno-Cancerology

Our projects aim to define therapeutic targets, characterise tumour-specific lymphocyte populations and develop immunotherapeutic strategies (vaccination or adoptive transfer of T cells) to combat solid tumours.

Research projects in Immuno-Infectious Diseases

Our projects aim to characterise the innate and adaptive responses to infection by a pathogen or virus with the aim of developing immunotherapeutic strategies (molecules or adoptive transfer of T cells) to combat infections.

Immunology and New Concepts in Immunotherapy

About us

Created in 2022, the INCIT(Immunology and New Concepts in Immunotherapy) research unit, directed by Frédéric Altare, is based on the desire to focus thescientific expertise of the immunology and immunotherapy teams on different pathological contexts: inflammation, cancer and infectious diseases.

Workforce

Publications since 2016

Doctoral students and post-docs

Locations - Nantes and Angers

Teams of specialists

INCIT brings together a wide range of immunology skills among its 4 teams, with a common objective:

To decipher the cellular and molecular mechanisms associated with immune responses to develop immunotherapeutic strategies.

Team 1

Modulation of immune and inflammatory responses.

Read more

Team 3

Anti-tumor immunosurveillance and immunotherapy.

Read more

Team 2

Clinical and translational research in proliferative and inflammatory skin diseases.

Read more

Team 4

Pathophysiology and immune responses to M. Ulcerans.

Read more

Our news

DARVAC: Inserm impact Santé

Mar 21, 2025 | New financing

Team 3 from INCIT Lab Inserm U1302 (Nantes) is part of the Inserm Impact Santé project DARVAC "Development of vaccines offering innovative early protection against non-viral cancers" based on ghost (Dark) proteins. The project is led by Jerome Galon, with Michel Salzet (Prism - Lille), Jean-Bastiste Latouche (Rouen), Olivier Adotevi (RIGHT - Besançon) and our Team (team 3, INCIT- François Lang,...

DARVAC: Inserm impact Santé

Mar 21, 2025 | New financing

Team 3 from INCIT Lab Inserm U1302 (Nantes) is part of the Inserm Impact Santé project DARVAC "Development of vaccines offering innovative early protection against non-viral cancers" based on ghost (Dark) proteins. The project is led by Jerome Galon, with Michel...

"Deciphering the immune escape mechanism of the Epstein-Barr oncovirus and exploiting it as a therapeutic target for cancers linked to this virus".

Mar 6, 2025 | Oncology, Immunotherapy, Seminar

Dr Marc Blondel (Faculté de Médecine et des Sciences de la Santé de l'UBO (Brest), invited by Team 2, will give a seminar entitled: Decrypting the immune escape mechanism of the Epstein-Barr oncovirus and exploiting it as a therapeutic target for cancers linked to this virus, on May 14 at 11.00 - Rooms 1, 2, 3 - IRS2, Nantes.

"Regulatory T cells control inflammatory and non-inflammatory pain through endogenous opioids".

Mar 6, 2025 | Oncology, Immunotherapy, Seminar

Dr Gilles Marodon (Inserm U1135 | CIMI-PARIS | SiRiC Curamus), invited by Team 3, will give a seminar entitled: Regulatory T cells control inflammatory and non-inflammatory pain through endogenous opioids , on March 14 at 11.00 - Rooms 1, 2, 3 - IRS2, Nantes